Question 1

What is a "normal" testosterone level for a man over 40?

Accepted Answer

Total testosterone in men over 40 follows a progressive decline of approximately 1–2% per year after age 30, with the clinical reference range of 300–1,000 ng/dL representing a population distribution rather than an ideal range, most men over 40 with symptoms of hypogonadism that improve on testosterone therapy have baseline levels below 400 ng/dL, while the 300 ng/dL threshold for diagnosing hypogonadism captures the most severe cases but leaves many symptomatic men with "normal" levels undertr

Question 2

Is TRT safe from a cardiovascular standpoint — what does the research say?

Accepted Answer

The TRAVERSE trial (Lincoff et al., NEJM, 2023), the largest RCT of TRT in hypogonadal men with cardiovascular risk factors (5,246 men, 33 months), found TRT non-inferior to placebo for major adverse cardiovascular events (MACE: heart attack, stroke, cardiovascular death), but found a 16% higher rate of atrial fibrillation and a 2.3-fold higher rate of pulmonary embolism in the TRT group, establishing that TRT requires individualized cardiovascular risk assessment, not population-wide prescripti

Question 3

What are the symptoms of low testosterone — the complete list?

Accepted Answer

The validated symptom constellation of hypogonadism in men includes: (1) sexual symptoms, reduced libido, erectile dysfunction, reduced spontaneous erections; (2) physical symptoms, loss of muscle mass and strength, increased body fat (particularly visceral), decreased bone density, fatigue, loss of body hair, reduced shaving frequency, gynecomastia; (3) psychological symptoms, depressed mood, reduced energy, poor concentration, irritability, sleep disturbance (Bhasin et al., J Clin Endocrinol M

Question 4

What's the difference between testosterone injections, gels, and pellets — which is best?

Accepted Answer

The three primary TRT delivery methods have different pharmacokinetic profiles and monitoring requirements: injectable testosterone (cypionate or enanthate, 50–100 mg weekly or 100–200 mg biweekly) produces supraphysiological peaks followed by troughs and has the most-studied safety data; transdermal gels (AndroGel, Testim) produce stable daily levels without peaks but carry a skin-transfer risk to female partners or children; subcutaneous pellets (Testopel) are implanted every 3–6 months and pr

Question 5

Will TRT make me infertile?

Accepted Answer

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis by reducing GnRH and LH secretion, which reduces intratesticular testosterone and stops or dramatically reduces sperm production, making conventional TRT incompatible with fertility goals in most men, with the degree of suppression variable but often significant within weeks of starting therapy (Crosnoe et al., Curr Opin Urol, 2013). This is the most important information for men under 45 considering TRT for the firs

Question 6

What labs should I monitor if I'm on TRT?

Accepted Answer

Men on TRT should have monitoring labs every 3–6 months initially and annually once stable: (1) total testosterone (target 400–700 ng/dL) + free testosterone + SHBG; (2) hematocrit/CBC, the most important safety lab on TRT; (3) estradiol (E2), TRT increases aromatization, potentially requiring anastrozole or dose reduction if symptomatic; (4) PSA, annual for men over 40; (5) blood pressure; (6) lipid panel + ApoB, testosterone can reduce HDL and alter lipid profile (Bhasin et al., J Clin Endocri

Question 7

Can I raise testosterone naturally without TRT — by how much?

Accepted Answer

Lifestyle interventions can raise total testosterone by approximately 10–25% in men with chronically dysregulated testosterone from reversible causes, the most effective interventions, ranked by evidence: (1) visceral fat reduction (5–10% body weight loss → 10–20% testosterone increase); (2) sleep restoration (increasing from 5–6 to 8 hours → 10–15% testosterone increase in trials); (3) resistance training (consistent program → 5–15% increase in low-normal men); (4) cortisol reduction (normaliza

Question 8

What is estradiol in men — and when does it become a problem on TRT?

Accepted Answer

Men naturally produce estradiol (E2) via aromatization of testosterone, a small but physiologically essential amount supporting bone density, libido, cognitive function, and cardiovascular health, but excess estradiol from supraphysiological testosterone conversion (as can occur with TRT, particularly in men with excess visceral fat and high aromatase activity) produces symptoms including gynecomastia, water retention, irritability, reduced libido, and disrupted sleep (Jankowska et al., Eur J He

Question 9

Can low testosterone cause depression?

Accepted Answer

Low testosterone is associated with depressive symptoms in men, not necessarily major depressive disorder, but a cluster of low mood, anhedonia, reduced motivation, irritability, and cognitive slowing that is partially mediated by testosterone's effects on serotonin, dopamine, and norepinephrine neurotransmitter systems, and testosterone replacement in hypogonadal men with these symptoms produces measurable improvement in mood scores in multiple RCTs (Zarrouf et al., J Clin Psychiatry, 2009). Th

Question 10

Is testosterone the key to building muscle after 40 — or is training more important?

Accepted Answer

The largest RCT on testosterone dose-response for muscle hypertrophy (Bhasin et al., NEJM, 1996) found that supraphysiological testosterone plus no training produced greater muscle mass and strength gains than natural testosterone plus weight training, confirming testosterone's role, but the critical finding for non-TRT men was that testosterone combined with training produced synergistic, greater-than-additive results, and that training alone produced meaningful gains at any physiological testo

Question 11

What is the difference between total testosterone, free testosterone, and bioavailable testosterone?

Accepted Answer

Total testosterone measures all testosterone in the blood, including that bound to sex hormone-binding globulin (SHBG, tightly bound and biologically inactive) and albumin (loosely bound, biologically available) and free testosterone (the small unbound fraction, approximately 1–3% of total, the most biologically active), free testosterone and albumin-bound testosterone together constitute "bioavailable testosterone," which is a better indicator of androgenic biological activity than total testos

Question 12

What is the TRAVERSE trial and what did it prove about TRT safety?

Accepted Answer

The TRAVERSE trial (Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men) enrolled 5,246 men aged 45–80 with hypogonadism (total testosterone below 300 ng/dL) and pre-existing cardiovascular disease or high cardiovascular risk, randomized to TRT (testosterone cypionate) or placebo, and followed for a mean of 33 months, finding TRT non-inferior to placebo for the composite cardiovascular endpoint of death, heart attack, and stroke,

Question 13

What is clomiphene / enclomiphene for testosterone — how does it compare to TRT?

Accepted Answer

Clomiphene citrate (off-label use) and enclomiphene (selective estrogen receptor modulator) stimulate the hypothalamic-pituitary axis to increase LH and FSH secretion, stimulating endogenous testosterone production, achieving testosterone increases of 150–300 ng/dL above baseline in most hypogonadal men while preserving spermatogenesis, making them the preferred option for men under 45 with fertility goals or men who want to avoid HPG axis suppression (Khera et al., J Urol, 2016). The trade-offs

Question 14

Are the testosterone clinics and telehealth TRT services that have proliferated actually safe?

Accepted Answer

Telehealth TRT services that prescribe testosterone after a single online questionnaire and a home testosterone test, without cardiovascular risk assessment, ECG, or in-person evaluation, are not practicing evidence-based medicine, the TRAVERSE trial data on atrial fibrillation and PE risk makes cardiovascular pre-screening a clinical imperative, and the hematocrit monitoring that all testosterone guidelines mandate requires ongoing laboratory supervision that many telehealth models do not adequ

Question 15

What is the connection between testosterone and prostate health?

Accepted Answer

Testosterone does not cause prostate cancer, the historical prohibition on TRT in men with prostate cancer was based on the "androgen saturation model" and has been progressively revised since Morgentaler's work established that physiological testosterone restoration does not drive prostate cancer progression in most contexts, but TRT can cause PSA elevation (average 0.3–0.5 ng/mL increase) and may accelerate growth of existing occult prostate cancer, making PSA monitoring mandatory and active p

Question 16

Does low testosterone cause cognitive decline?

Accepted Answer

Low testosterone is associated with poorer cognitive performance on tests of spatial ability, verbal fluency, and processing speed in observational studies of middle-aged men, and the proposed mechanism involves testosterone's neuroprotective effects through androgen receptor activation in the hippocampus and prefrontal cortex, its promotion of BDNF (brain-derived neurotrophic factor) signaling, and its role in maintaining myelin integrity, but whether TRT reverses this cognitive decline in clin

Question 17

How quickly does testosterone therapy work — what should I expect?

Accepted Answer

Testosterone therapy effects emerge at different timescales: (1) libido improves within 3–4 weeks; (2) erectile function improves within 6–8 weeks (partial improvement, full erectile response may take 3–6 months); (3) energy and mood improve within 3–6 weeks; (4) muscle mass increase requires 3–6 months with concurrent resistance training; (5) fat mass reduction requires 6–12 months; (6) bone density improvement requires 1–2 years (Zitzmann, Eur J Endocrinol, 2007). Setting realistic expectation

Question 18

What is polycythemia from TRT and how dangerous is it?

Accepted Answer

Testosterone-induced polycythemia (elevated red blood cell mass) occurs in approximately 5–20% of men on TRT, driven by testosterone stimulating erythropoietin production in the kidneys, hematocrit above 54% substantially increases blood viscosity, impairs microvascular flow, and increases risk of deep vein thrombosis, pulmonary embolism, and stroke, making hematocrit monitoring every 3–6 months on TRT a clinical imperative, not an optional measure (Calof et al., J Gerontol A Biol Sci Med Sci, 2

Question 19

Does testosterone affect sleep apnea?

Accepted Answer

Testosterone, particularly at supraphysiological doses from TRT, can worsen or precipitate obstructive sleep apnea, likely through effects on upper airway dilator muscle function, changes in respiratory drive, and reduced chemoreceptor sensitivity, and men with undiagnosed sleep apnea who start TRT may experience significant worsening of their sleep architecture and symptoms (Cistulli et al., Thorax, 1994). The TRT-sleep apnea interaction creates a double clinical risk: TRT worsens sleep apnea →

Question 20

I'm 44 and my testosterone is 380 ng/dL. My doctor says it's normal. What should I do?

Accepted Answer

A total testosterone of 380 ng/dL at age 44 is within the laboratory reference range (>300 ng/dL) but is below the 25th percentile for men aged 20–39, meaning 75% of young healthy men have higher testosterone, and the clinical decision depends entirely on whether you have symptoms attributable to hypogonadism (libido decline, erectile difficulty, muscle loss, fatigue, depressed mood), because a number without symptoms does not meet hypogonadism diagnostic criteria (Bhasin et al., J Clin Endocrin

Question 21

What are the long-term effects of TRT — is it safe to take indefinitely?

Accepted Answer

Long-term TRT (beyond 10 years) has limited RCT data but substantial observational data, the most clinically meaningful long-term concerns are: (1) persistent HPG axis suppression making natural testosterone production unlikely to resume if TRT is stopped; (2) cumulative polycythemia risk requiring ongoing hematocrit management; (3) prostate size increase (though not prostate cancer risk increase in current evidence); (4) potential for cardiovascular effects not captured in 3-year trials, the TR

Question 22

What should I know about testosterone and the heart — the one-paragraph clinical summary?

Accepted Answer

Testosterone and cardiovascular health have a complex, bidirectional relationship: low testosterone is associated with higher cardiovascular mortality (observational data), TRT in hypogonadal men does not increase heart attack or stroke risk (TRAVERSE RCT), but TRT does increase atrial fibrillation risk by 16% and PE risk 2.3-fold (TRAVERSE), making TRT a therapy requiring cardiovascular pre-screening (ECG, blood pressure, hematocrit, AF risk assessment) by a qualified physician, ongoing monitor

Testosterone / TRT